Difference between revisions of "Galsky MD, et al. Clin. Cancer Res. (2014) cited as Ref 632 in DOI: 10.1038/s41392-020-0110-5 (Q9895)"

@@ Property / Publication Date @@
+Timestamp +2014-01-01T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 year
Before 0
After 0
-Timestamp
++2014-01-01T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+year
 Before
 After
@@ Property / Publication Date: 2014 / rank @@
+Normal rank
@@ Property / Published In Name String @@
+Clin. Cancer Res.
@@ Property / Published In Name String: Clin. Cancer Res. / rank @@
+Normal rank
@@ Property / Volume @@
@@ Property / Volume: 20 / rank @@
+Normal rank
@@ Property / title @@
+A phase I trial of LY2510924 a CXCR4 peptide antagonist in patients with advanced cancer (English)
+Normal rank
@@ Property / Page(s) @@
+-3588
@@ Property / Page(s): 3581-3588 / rank @@
+Normal rank

Latest revision as of 15:47, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

Language	Label	Description	Also known as
English	Galsky MD, et al. Clin. Cancer Res. (2014) cited as Ref 632 in DOI: 10.1038/s41392-020-0110-5	Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8